FerriScan gains independent validation

Perth-based Resonance Health Ltd has gained independent international validation for its FerriScan liver treatment. The announcement was made at the American Society of Hematology conference.
FerriScan is a regulated magnetic resonance imaging liver iron test which provides high sensitivity and specificity determination of iron concentration throughout the liver.
Resonance Health managing director Dr James Williams said the independent validation of the test came from Swiss pharmaceutical company, Novartis Pharma AG, who had been using the test in clinical studies.
"Liver biopsy is the gold standard," he said. "Novartis studied several tests including FerriScan and we compared favourably to the gold standard.
"Receiving independent validation means a greater level of credibility in the medical community.
"There is now a greater awareness of FerriScan resulting in more clinics wanting to use the tests and greater sales."
The ASH conference is attended by around 20,000 delegates and is being held in Atlanta from 10th to 13th of December.
In October Resonance Health's wholly owned subsidiary, Resonance Health Analysis Services, was awarded a WA Department of Health supply contract to supply FerriScan throughout the public hospital system.